Don't close the book on tocilizumab for the treatment of severe COVID-19 pneumonia-the jury is still out: The Kuwait experience

This cross-sectional observational study aims to report preliminary data from the first experience using tocilizumab for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in three of Kuwait's largest public hospitals City. This chart review study examined the...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-08, Vol.16 (8), p.e0254379
Main Authors: Al-Shamali, Yousef, M Ali, Yaser, Al-Shamali, Rawan A, Al-Melahi, Maryam, Al-Shammari, Farah R, Alsaber, Ahmad, Al-Adsani, Wasl
Format: Article
Language:English
Subjects:
Age
Aged
Antibodies, Monoclonal, Humanized - therapeutic use
Arthritis
Bacterial pneumonia
Biology and Life Sciences
Cardiovascular disease
Care and treatment
Comorbidity
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Cross-Sectional Studies
Cytokines
Drug dosages
Female
Gastroenterology
Health services
Hospitals
Humans
Immunosuppressive agents
Infections
Internal medicine
Kuwait - epidemiology
Male
Medicine and Health Sciences
Middle Aged
Monoclonal antibodies
Mortality
Patients
People and Places
Physical Sciences
Pneumonia
Pneumonia - drug therapy
Retrospective Studies
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Ventilators
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This cross-sectional observational study aims to report preliminary data from the first experience using tocilizumab for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in three of Kuwait's largest public hospitals City. This chart review study examined the benefits of tocilizumab treatment among 127 patients diagnosed with severe coronavirus disease of 2019 (COVID-19) pneumonia. 90 of 127 patients (71%) survived. Mortality was highest in the elderly with multiple medical conditions. Despite the small sample size and retrospective nature of the work, our findings are consistent with recent studies suggesting tocilizumab administration in patients presenting with severe COVID pneumonia with associated hyperinflammatory features conferred mortality benefit.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0254379